Checkpoint inhibitors do not kill cancers. They remove checkpoints which prevent activated T cells from doing this. Checkpoints put a brake on normal immunologic mechanisms to eliminate cancers.
Waning of PD1 anticancer effect can be due to T cell exhaustion which can be overcome by our fusion protein, eftilagimod.
Eftilagimod allows reprogramming cellular immunity adapting to changing antigen environments. This is active immunotherapy c/w CAR T cell passive immunotherapies.
This paper points out that PD1 monotherapy may already be outdated and there is a need to include eftilagimod or similar therapies for sustained improvements.
Checkpoint inhibitors do not kill cancers. They remove...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.5¢ | 43.0¢ | $944.4K | 2.126M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18198 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 12500 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
0.010 ( 0.80 %) |
||||
| Open | High | Low | Volume | ||
| 43.5¢ | 45.0¢ | 43.0¢ | 184791 | ||
| Last updated 15.58pm 31/05/2024 ? | |||||
| IMM (ASX) Chart |